This site is intended for healthcare professionals
Drug news

NICE now finds Firmagon (degarelix) to be not cost effective as a prostate cancer treatment- Ferring

Read time: 1 mins
Last updated:8th Jun 2015
Published:8th Jun 2015
Source: Pharmawand

The National Institute for Care and Clinical Excellence (NICE) has reversed an earlier decision regarding Firmagon (degarelix) from Ferring and concluded that the drug is not a cost-effective treatment for advanced, hormone-dependent prostate cancer compared with the current standard of care. The independent Appraisal Committee of NICE had previously provisionally supported the drug’s use in patients with signs and symptoms of spinal cord compression, but clinical experts said that using the treatment at this stage would not be appropriate.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights